×
About 2,581 results

ALLMedicine™ Apolipoprotein A-I Center

Research & Reviews  1,287 results

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability...
https://doi.org/10.1194/jlr.RA120000920
Journal of Lipid Research; Nilsson O, Lindvall M et. al.

Jan 7th, 2021 - Apolipoprotein A-I (ApoA-I) of high density lipoproteins (HDLs) is essential for the transportation of cholesterol between peripheral tissues and the liver. However, specific mutations in ApoA-I of HDLs are responsible for a late-onset systemic am...

Intracellular AIBP (Apolipoprotein A-I Binding Protein) Regulates Oxidized LDL (Low-Den...
https://doi.org/10.1161/ATVBAHA.120.315485
Arteriosclerosis, Thrombosis, and Vascular Biology; Choi SH, Agatisa-Boyle C et. al.

Dec 28th, 2020 - Atherosclerotic lesions are often characterized by accumulation of OxLDL (oxidized low-density lipoprotein), which is associated with vascular inflammation and lesion vulnerability to rupture. Extracellular AIBP (apolipoprotein A-I binding protein...

Apolipoprotein A-I mimetics attenuate macrophage activation in chronic treated HIV.
https://doi.org/10.1097/QAD.0000000000002785
AIDS (London, England); Mu W, Sharma M et. al.

Dec 11th, 2020 - Despite antiretroviral therapy (ART), there is an unmet need for therapies to mitigate immune activation in HIV infection. The goal of this study is to determine whether the apoA-I mimetics 6F and 4F attenuate macrophage activation in chronic HIV....

Identification and differential expression of serotransferrin and apolipoprotein A-I in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694411
BMC Infectious Diseases; Barik SK, Mohanty KK et. al.

Nov 28th, 2020 - Plasma proteins are known to interfere the drug metabolism during therapy. As limited information is available regarding the role of plasma proteins in HIV drug resistance during ART in HIV/AIDS patients, the present study aimed to identify and ch...

Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and ...
https://doi.org/10.1111/bcp.14666
British Journal of Clinical Pharmacology; Zheng B, Duffy D et. al.

Nov 20th, 2020 - To characterize relationships between apolipoprotein A-I (apoA-I) exposure and cholesterol efflux capacity (CEC) and covariate effects following CSL112 (apoA-I [human]) administration in an integrated population including acute myocardial infarcti...

see more →

Clinicaltrials.gov  1,291 results

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability...
https://doi.org/10.1194/jlr.RA120000920
Journal of Lipid Research; Nilsson O, Lindvall M et. al.

Jan 7th, 2021 - Apolipoprotein A-I (ApoA-I) of high density lipoproteins (HDLs) is essential for the transportation of cholesterol between peripheral tissues and the liver. However, specific mutations in ApoA-I of HDLs are responsible for a late-onset systemic am...

Intracellular AIBP (Apolipoprotein A-I Binding Protein) Regulates Oxidized LDL (Low-Den...
https://doi.org/10.1161/ATVBAHA.120.315485
Arteriosclerosis, Thrombosis, and Vascular Biology; Choi SH, Agatisa-Boyle C et. al.

Dec 28th, 2020 - Atherosclerotic lesions are often characterized by accumulation of OxLDL (oxidized low-density lipoprotein), which is associated with vascular inflammation and lesion vulnerability to rupture. Extracellular AIBP (apolipoprotein A-I binding protein...

Apolipoprotein A-I mimetics attenuate macrophage activation in chronic treated HIV.
https://doi.org/10.1097/QAD.0000000000002785
AIDS (London, England); Mu W, Sharma M et. al.

Dec 11th, 2020 - Despite antiretroviral therapy (ART), there is an unmet need for therapies to mitigate immune activation in HIV infection. The goal of this study is to determine whether the apoA-I mimetics 6F and 4F attenuate macrophage activation in chronic HIV....

Identification and differential expression of serotransferrin and apolipoprotein A-I in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694411
BMC Infectious Diseases; Barik SK, Mohanty KK et. al.

Nov 28th, 2020 - Plasma proteins are known to interfere the drug metabolism during therapy. As limited information is available regarding the role of plasma proteins in HIV drug resistance during ART in HIV/AIDS patients, the present study aimed to identify and ch...

Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and ...
https://doi.org/10.1111/bcp.14666
British Journal of Clinical Pharmacology; Zheng B, Duffy D et. al.

Nov 20th, 2020 - To characterize relationships between apolipoprotein A-I (apoA-I) exposure and cholesterol efflux capacity (CEC) and covariate effects following CSL112 (apoA-I [human]) administration in an integrated population including acute myocardial infarcti...

see more →

News  3 results

ApoA-I Therapies Flop for Plaque Reduction
https://www.medpagetoday.com/cardiology/atherosclerosis/74221

Jul 25th, 2018 - Action Points Two studies of recombinant apolipoprotein A-I (the major HDL apolipoprotein) products failed to show an effect on coronary plaque volume assessed by intravascular ultrasound (IVUS). Note that based on these studies, the development o...

First Oral ApoA-I Booster Shows Mixed Results
https://www.mdedge.com/endocrinology/article/54195/obesity/first-oral-apoa-i-booster-shows-mixed-results
Bruce Jancin

Apr 1st, 2011 - CHICAGO – A novel oral drug designed to increase apolipoprotein A-I synthesis and thereby enhance HDL functionality showed mixed results in its first major clinical trial. The 299-patient, 12-week, randomized, double-blind ApoA-I Synthesis Stimula.

Infusion of Milano Apoprotein Causes Rapid Regression of Atherosclerosis
https://www.medscape.com/viewarticle/463893

Nov 3rd, 2003 - Nov. 4, 2003 — Infusion of the Milano apoprotein A rapidly causes regression of atherosclerosis in patients with acute coronary syndromes (ACS), according to the results of a preliminary randomized trial published in the Nov. 5 issue of The Journa...

see more →